TL;DR
The Fox Insight study has created a large, longitudinal dataset of patient-reported outcomes and genetic information for individuals with and without Parkinson's disease. This publicly accessible resource aims to accelerate Parkinson's research by providing a rich, multi-modal dataset for discovery, validation, and reproducibility.
What Problem Does This Paper Address?
Parkinson's disease (PD) is a complex neurodegenerative disorder with highly variable manifestations, making it challenging to understand its progression, underlying causes, and develop effective treatments. Traditional clinical trials often struggle with recruitment diversity and capturing the full spectrum of patient experiences. This variability necessitates larger, longitudinal studies that can capture a deeper patient perspective and integrate diverse data types. The authors highlight the need for more comprehensive data to overcome these challenges and advance PD research.
Methods
Fox Insight employs a multi-pronged approach to data collection:
- Routine Longitudinal Assessments: Participants complete regular health and medical questionnaires online. These assessments are tailored based on whether the participant has a Parkinson's diagnosis, covering motor symptoms, non-motor symptoms, quality of life, and lifestyle.
- One-Time Questionnaires: These are deployed to gather additional, specific information, such as environmental exposures, healthcare preferences, and the financial and social impact of PD. This allows for targeted data collection on emerging research questions.
- Genetic Data Collection: Participants can opt-in to provide genetic data through saliva samples, which are then genotyped. This allows for the exploration of genetic predispositions and modifiers of Parkinson's disease.
The study leverages an agile-developed web application for data collection and management, ensuring flexibility and phased deployment of new features.
Datasets
The primary dataset introduced is the Fox Insight dataset, which comprises:
- Patient-Reported Outcomes (PROs): Collected through routine longitudinal assessments and one-time questionnaires.
- Genetic Data: Genotype data from participants, including approximately 600,000 single nucleotide polymorphisms (SNPs).
This data is made accessible to qualified researchers through the Fox DEN (Data Exploration Network) platform.
Key Insights and Ideas
- The Power of Online Data Collection: Fox Insight demonstrates the feasibility and effectiveness of large-scale, online data collection for a complex disease like Parkinson's. This approach overcomes geographical barriers and potentially reduces participant burden compared to in-person studies.
- Integrating Multi-Modal Data: The study's strength lies in its integration of longitudinal PROs with genetic data. This allows for a more holistic understanding of Parkinson's disease, enabling researchers to explore gene-environment interactions and genetic influences on disease progression and symptoms.
- Democratizing Data Access: By making the PRO data and a pre-selected set of genetic variants publicly available through Fox DEN, the study aims to foster reproducibility and accelerate research by providing a rich resource for a broad range of investigators.
- Addressing Recruitment Challenges: The online recruitment strategy and the inclusion of participants both with and without Parkinson's disease aim to create a more representative cohort than traditional clinical trials.
Key Results
As of the data descriptor's publication (Q1'19), Fox Insight had enrolled over 30,000 individuals, with over 22,000 diagnosed with Parkinson's disease, making it one of the largest prospectively followed PD cohorts.
- Participant Demographics: The PD cohort has a mean age of 66 years and an average diagnosis duration of over 6 years.
- Data Completion Rates: High rates of cross-sectional data completion were observed (90.5% for PD participants). Longitudinal engagement showed a drop-off of approximately 10.1% from the first to the last assessment within a period.
- Genetic Sub-Study: Approximately 5,880 participants agreed to genetic data collection, with 5,092 genotyped.
- Data Validation: Genetic data validation showed a high match rate (99.76%) between sex chromosome and self-reported sex.
Limitations and Future Work
- Self-Reported Data: While validated instruments are used, the reliance on self-reported data introduces potential for recall bias or inaccuracies.
- Beta Participants: Data from "beta participants" (those who joined before the official launch) may have inconsistencies due to questionnaire versioning and platform troubleshooting.
- Missing Data: Some demographic data is missing due to platform glitches or participant drop-off.
- Full SNP Data Access: Access to the complete set of ~600,000 SNPs requires a separate request and institutional review, indicating a tiered access model for the most detailed genetic information.
Future work will likely involve continued data collection, expansion of the cohort, and further analysis of the integrated PRO and genetic data to uncover new insights into Parkinson's disease. The flexibility of the platform also allows for the incorporation of new research questions and data types as the field evolves.
Summary updated